Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept + Pemetrexed + Cisplatin in Advanced Carcinoma and NSCLC
NCT00794417Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2008
- Primary completion
- Jun 2011
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of aflibercept in non-small cell lung cancer (NSCLC), carcinoma, sponsored by Regeneron Pharmaceuticals. Started Nov 2008; status: terminated.
02
Drugs
aflibercept
03
Conditions
non-small cell lung cancer (NSCLC)carcinoma
Beyond the preview
Go deeper on NCT00794417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00794417.